News

 

These brands have combined annualized revenues of approximately US$ 160 million and address  medical conditions across several therapeutic areas. Under the terms of the agreements, Novartis will continue to  distribute these brands, for a certain period, pending transfer of all marketing authorizations to Sun Pharma’s
subsidiary. 

The acquired brands will be marketed by a reliable and established local marketing partner under the  Sun Pharma label. 

The local marketing partner will also be responsible for distribution of the brands.

Commenting on the acquisition, Dilip Shanghvi, Managing Director, Sun Pharma said, “Japan is a market of strategic interest for us. This acquisition marks Sun Pharma’s foray into the Japanese prescription market and provides us an opportunity to build a larger product portfolio in the future.”
 
As per the December-2015 IMS Data, the size of the Japanese pharmaceutical market was estimated at US$ 73  Billion, accounting for over 7% of the US$ 1 Trillion global pharmaceutical market.